Quinazolin-2-Amine LRRK2 Inhibitors for Brain-Penetrant Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and other related disorders lack effective therapies targeting the LRRK2 kinase, which is implicated in these conditions, leading to unmet medical needs for selective and brain-penetrant inhibitors.
Innovation Solution
Development of N-(heteroaryl)quinazolin-2-amine derivatives that exhibit potent and selective LRRK2 inhibitory activity, offering potential therapeutic benefits across various diseases and disorders associated with LRRK2 kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurodegenerative diseases are used, then existing therapy options are available, but effective therapies targeting LRRK2 kinase are lacking
Solution Approach 1:
The patent applies parameter changes by optimizing the chemical structure of quinazoline derivatives through systematic modification of substituents (R1-R6 groups) to achieve potent and selective LRRK2 inhibition. The structure-activity relationship studies involve changing molecular parameters such as heteroaryl groups, alkyl chains, and functional groups to enhance binding affinity and selectivity for LRRK2 kinase while maintaining brain penetration capability.
2Reliability
If selective LRRK2 inhibitors are developed, then targeted therapy is achieved, but brain penetration capability must be ensured
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituents at particular positions on the quinazoline core structure to achieve both selectivity and brain penetration. For example, specific R2 and R3 substituents are chosen to enhance blood-brain barrier permeability while R4 and R5 groups are optimized for selective binding to LRRK2 kinase, allowing different parts of the molecule to fulfill different functional requirements.
3Productivity
If potent LRRK2 inhibition is achieved, then therapeutic potential increases, but selectivity among kinase targets must be maintained
Solution Approach 1:
The patent applies segmentation by dividing the quinazoline molecule into distinct functional segments: the core quinazoline-2-amine structure provides potent kinase inhibition, while specific heteroaryl substituents (R1-R6) provide selectivity for LRRK2 over other kinases. This modular approach allows optimization of each segment independently to achieve both high potency and selectivity.
Data Source
AI summary
The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.